FMP
Sep 27, 2021 8:03 PM - Davit Kirakosyan
Analysts at Oppenheimer increased their price target on Prothena Corporation plc (NASDAQ:PRTA) to $100 from $90, as they refresh their favorable outlook on the company due to the recent update of FDA's Surrogate Endpoint Table, which now includes a reduction in amyloid-ß plaque for mAbs in mild-AD patients as appropriate for accelerated approval.
The analysts see confirmation that the company should benefit from regulatory precedence plus BIIB's launch efforts, noting that BIIB's Aduhelm was approved based on this surrogate endpoint.
Sep 11, 2023 - Rajnish Katharotiya
During this post we are going to perform an industry analysis with Python. We will build, analyse and compare all stocks operating within an industry. To do so, we will pick an industry and get all important financial metrics for companies operating in that industry. Then, we will use a couple of fi...
Sep 11, 2023 - Rajnish Katharotiya
Price to Earnings is one of the key metrics use to value companies using multiples. The P/E ratio and other multiples are relative valuation metrics and they cannot be looked at in isolation. One of the problems with the P/E metric is the fact that if we are in the peak of a business cycle, earni...
Sep 11, 2023 - Rajnish Katharotiya
Would you like to know how your portfolio is performing and how much risk you are taking? In this post, you will learn how to measure portfolio risk and calculate portfolio returns using Python. We will see step by step how to calculate the risk and returns of a portfolio containing four stocks Appl...